James Bradner goes to Novartis and TEN-010 goes to Roche. There...

James Bradner goes to Novartis and TEN-010 goes to Roche. There is excellent background on the development of TEN-010 in the radio interview The Myc Problem in Myeloma. The information isn't just of academic interest but provides a basis for understanding the opportunity for Phylogica in targeting Myc.

Bradner discusses the three approaches used by his lab in relation to Myc: the upstream targeting of Myc, the collaborators of Myc and directly targeting Myc. TEN-010 was developed to inhibit a bromodomain, one of the collaborators of Myc. As Bradner observes in the interview, although TEN-010 doesn't target Myc, nonetheless its mechanism of action can turn off Myc.

Directly targeting Myc remains elusive which is why it one of the Grand Challenges to be funded by Cancer Research UK. Phylogica have found a unique way forward through its novel drug discovery technology. Whether it will succeed where all others have failed remains to be seen but at this stage of development - with the data generated to date - there is much to be excited about.